Raymond James analyst Laura Prendergast initiated coverage of Mural Oncology with a Strong Buy rating and $18 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MURA:
- Mural Oncology’s Investor Day Highlights Cancer Treatment Trials
- Mural Oncology provides update on ARTISTRY-7 at Investor Day
- Mural Oncology provides update on ARTISTRY-6 cohort 2 at Investor Day
- Mural Oncology plans to nominate candidate for IL-18 program by year-end
- Mural Oncology to host first virtual Investor Day
